McKeith I G, Galasko D, Kosaka K, Perry E K, Dickson D W, Hansen L A, Salmon D P, Lowe J, Mirra S S, Byrne E J, Lennox G, Quinn N P, Edwardson J A, Ince P G, Bergeron C, Burns A, Miller B L, Lovestone S, Collerton D, Jansen E N, Ballard C, de Vos R A, Wilcock G K, Jellinger K A, Perry R H
Department of Old Age Psychiatry, Newcastle General Hospital, Newcastle upon Tyne, U.K.
Neurology. 1996 Nov;47(5):1113-24. doi: 10.1212/wnl.47.5.1113.
Recent neuropathologic autopsy studies found that 15 to 25% of elderly demented patients have Lewy bodies (LB) in their brainstem and cortex, and in hospital series this may constitute the most common pathologic subgroup after pure Alzheimer's disease (AD). The Consortium on Dementia with Lewy bodies met to establish consensus guidelines for the clinical diagnosis of dementia with Lewy bodies (DLB) and to establish a common framework for the assessment and characterization of pathologic lesions at autopsy. The importance of accurate antemortem diagnosis of DLB includes a characteristic and often rapidly progressive clinical syndrome, a need for particular caution with neuroleptic medication, and the possibility that DLB patients may be particularly responsive to cholinesterase inhibitors. We identified progressive disabling mental impairment progressing to dementia as the central feature of DLB. Attentional impairments and disproportionate problem solving and visuospatial difficulties are often early and prominent. Fluctuation in cognitive function, persistent well-formed visual hallucinations, and spontaneous motor features of parkinsonism are core features with diagnostic significance in discriminating DLB from AD and other dementias. Appropriate clinical methods for eliciting these key symptoms are described. Brainstem or cortical LB are the only features considered essential for a pathologic diagnosis of DLB, although Lewy-related neurites, Alzheimer pathology, and spongiform change may also be seen. We identified optimal staining methods for each of these and devised a protocol for the evaluation of cortical LB frequency based on a brain sampling procedure consistent with CERAD. This allows cases to be classified into brainstem predominant, limbic (transitional), and neocortical subtypes, using a simple scoring system based on the relative distribution of semiquantitative LB counts. Alzheimer pathology is also frequently present in DLB, usually as diffuse or neuritic plaques, neocortical neurofibrillary tangles being much less common. The precise nosological relationship between DLB and AD remains uncertain, as does that between DLB and patients with Parkinson's disease who subsequently develop neuropsychiatric features. Finally, we recommend procedures for the selective sampling and storage of frozen tissue for a variety of neurochemical assays, which together with developments in molecular genetics, should assist future refinements of diagnosis and classification.
最近的神经病理学尸检研究发现,15%至25%的老年痴呆患者脑干和皮质中存在路易小体(LB),在医院病例系列中,这可能是仅次于单纯阿尔茨海默病(AD)的最常见病理亚组。路易体痴呆协会召开会议,制定路易体痴呆(DLB)临床诊断的共识指南,并建立尸检时病理病变评估和特征描述的通用框架。DLB生前准确诊断的重要性包括其特征性且通常进展迅速的临床综合征、使用抗精神病药物时需格外谨慎,以及DLB患者可能对胆碱酯酶抑制剂特别敏感。我们确定进行性致残性精神障碍进展为痴呆是DLB的核心特征。注意力障碍以及不成比例的问题解决和视觉空间困难通常出现较早且较为突出。认知功能波动、持续的逼真视幻觉以及帕金森病的自发运动特征是在区分DLB与AD及其他痴呆时具有诊断意义的核心特征。本文描述了引出这些关键症状的合适临床方法。脑干或皮质LB是DLB病理诊断唯一被认为必不可少的特征,不过也可能见到路易体相关神经突、阿尔茨海默病病理改变和海绵状改变。我们确定了针对每种情况的最佳染色方法,并根据与CERAD一致的脑取样程序设计了评估皮质LB频率的方案。这使得病例能够使用基于半定量LB计数相对分布的简单评分系统分为脑干为主型、边缘(过渡)型和新皮质亚型。阿尔茨海默病病理改变在DLB中也经常出现,通常表现为弥漫性或神经炎斑块,新皮质神经原纤维缠结则较少见。DLB与AD之间的确切疾病分类关系仍不确定,DLB与随后出现神经精神特征的帕金森病患者之间的关系也不明确。最后,我们推荐了用于多种神经化学检测的冷冻组织选择性取样和保存程序,这些程序连同分子遗传学的发展,应有助于未来诊断和分类的完善。